Natreon granted patent for its Terminalia chebula extract Ayuflex
Natreon has been granted a U.S. Patent (US 10,500,240) on Terminalia chebula.
Photo © Shutterstock.com/jovan vitanovski
Natreon (New Brunswick, NJ) has been granted a U.S. Patent (US 10,500,240) on Terminalia chebula. The primary claim in the patent is “a method of treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.”
The secondary claim in this patent is “a method of reducing pain and inflammation in an individual with osteoarthritis in need thereof, comprising orally administering to the individual in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.”
This latest patent brings Natreon’s latest patent portfolio to 24 active patents, as well as 40 published clinical trial.
